{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T18:11:03Z","timestamp":1783361463580,"version":"3.54.6"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2021,1,9]],"date-time":"2021-01-09T00:00:00Z","timestamp":1610150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,8,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Published data is limited on the prevalence and risk of recurrence of extraintestinal invasive Escherichia coli infections (IEIs) in the United States.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The analysis included all inpatient and hospital-based outpatient visits occurring between 2009 and 2016 at hospitals with continuous microbiology data submission to the Premier Healthcare Database for 90 days before and 12 months after the admission or visit. IEI was defined as having positive E. coli culture from a normally sterile site (eg, blood, cerebrospinal fluid). The prevalence of IEI, 12-month risk of recurrent IEI, and antibiotic resistance were assessed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Overall, 144 944 725 hospital visits among 37 207 510 patients were analyzed, and 71 909 IEI events occurred in 67 583 patients, corresponding to an IEI prevalence of 0.50 events per 1000 visits and 1.82 events per 1000 patients. Recurrence was common: 26.9 per 1000 patients had a recurrent IEI in the 12 months after their infection. Most infections were community acquired (66.4%), and urosepsis was most common clinical syndrome (66.0%). The 30-day risk of IEI among patients undergoing transrectal ultrasound\u2013guided prostate biopsy was high: 5.03 events per 1000 patients. Among all IEI cases with antibiotic susceptibility testing, 9.18% were resistant to extended-spectrum cephalosporins, 28.22% to fluoroquinolones, and 0.14% to carbapenems. Resistance to extended-spectrum cephalosporins increased from 5.46% to 12.97% during the 8-year study period.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This real-world study indicates a substantial burden of IEI and recurrent IEI exists in the United States, as well as increasing resistance to extended-spectrum cephalosporins. Future research should explore risk factors of recurrent IEI aiming to effectively prevent such infections.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciab005","type":"journal-article","created":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T20:26:18Z","timestamp":1610137578000},"page":"565-574","source":"Crossref","is-referenced-by-count":46,"title":["Epidemiology of Invasive <i>Escherichia coli<\/i> Infection and Antibiotic Resistance Status Among Patients Treated in US Hospitals: 2009\u20132016"],"prefix":"10.1093","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1287-5416","authenticated-orcid":false,"given":"Elizabeth","family":"Begier","sequence":"first","affiliation":[{"name":"Vaccine Clinical Research and Development, Pfizer, Pearl River, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning A","family":"Rosenthal","sequence":"additional","affiliation":[{"name":"Premier Applied Sciences, Premier Healthcare Solutions, Charlotte, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"Gurtman","sequence":"additional","affiliation":[{"name":"Vaccine Clinical Research and Development, Pfizer, Pearl River, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Kartashov","sequence":"additional","affiliation":[{"name":"Premier Applied Sciences, Premier Healthcare Solutions, Charlotte, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert G K","family":"Donald","sequence":"additional","affiliation":[{"name":"Pfizer Vaccine Research, Pearl River, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen P","family":"Lockhart","sequence":"additional","affiliation":[{"name":"Vaccine Clinical Research and Development, Pfizer, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,1,9]]},"reference":[{"key":"2021081616412079600_CIT0001","doi-asserted-by":"crossref","first-page":"71","DOI":"10.4161\/gmic.19182","article-title":"Infection strategies of enteric pathogenic Escherichia coli","volume":"3","author":"Clements","year":"2012","journal-title":"Gut Microbes"},{"key":"2021081616412079600_CIT0002","doi-asserted-by":"crossref","first-page":"587","DOI":"10.3109\/00365548.2011.572907","article-title":"Clinical implications of healthcare-associated infection in patients with community-onset acute pyelonephritis","volume":"43","author":"Ha","year":"2011","journal-title":"Scand J Infect Dis"},{"key":"2021081616412079600_CIT0003","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1089\/fpd.2007.0087","article-title":"Extraintestinal pathogenic Escherichia coli","volume":"4","author":"Smith","year":"2007","journal-title":"Foodborne Pathog Dis"},{"key":"2021081616412079600_CIT0004","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1128\/AAC.00143-10","article-title":"Costs of bloodstream infections caused by Escherichia coli and influence of extended-spectrum-beta-lactamase production and inadequate initial antibiotic therapy","volume":"54","author":"Tumbarello","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2021081616412079600_CIT0005","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/femsre\/fuw005","article-title":"Escherichia coli: an old friend with new tidings","volume":"40","author":"Vila","year":"2016","journal-title":"FEMS Microbiol Rev"},{"key":"2021081616412079600_CIT0006","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1093\/cid\/ciaa210","article-title":"Epidemiology of Escherichia coli bacteremia: a systematic literature review","volume":"72","author":"Bonten","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2021081616412079600_CIT0007","doi-asserted-by":"crossref","first-page":"e1001104","DOI":"10.2807\/1560-7917.ES.2016.21.35.30329","article-title":"Descriptive epidemiology of Escherichia coli bacteraemia in England, April 2012 to March 2014","volume":"21","author":"Bou-Antoun","year":"2016","journal-title":"Euro Surveill"},{"key":"2021081616412079600_CIT0008","doi-asserted-by":"crossref","first-page":"30329","DOI":"10.1371\/journal.pmed.1001104","article-title":"Mortality and hospital stay associated with resistant Staphylococcus aureus and Escherichia coli bacteremia: estimating the burden of antibiotic resistance in Europe","volume":"8","author":"de Kraker","year":"2011","journal-title":"PLoS Med"},{"key":"2021081616412079600_CIT0009","first-page":"e000190","article-title":"Genetic analysis of invasive Escherichia coli in Scotland reveals determinants of healthcare-associated versus community- acquired infections","volume":"4","author":"Goswami","year":"2018","journal-title":"Microb Genom"},{"key":"2021081616412079600_CIT0010","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1111\/1469-0691.12089","article-title":"Healthcare-associated, community-acquired and hospital-acquired bacteraemic urinary tract infections in hospitalized patients: a prospective multicentre cohort study in the era of antimicrobial resistance","volume":"19","author":"Horcajada","year":"2013","journal-title":"Clin Microbiol Infect"},{"key":"2021081616412079600_CIT0011","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ijantimicag.2010.05.009","article-title":"Risk factors and treatment outcomes of community-onset bacteraemia caused by extended-spectrum beta-lactamase-producing Escherichia coli.","volume":"36","author":"Kang","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"2021081616412079600_CIT0012","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/1469-0691.12144","article-title":"Incidence of bloodstream infection: a review of population-based studies","volume":"19","author":"Laupland","year":"2013","journal-title":"Clin Microbiol Infect"},{"key":"2021081616412079600_CIT0013","doi-asserted-by":"crossref","first-page":"243","DOI":"10.20411\/pai.v1i2.123","article-title":"Fluoroquinolone-resistant Escherichia coli infections after transrectal biopsy of the prostate in the veterans affairs healthcare system","volume":"1","author":"Saade","year":"2016","journal-title":"Pathog Immun"},{"key":"2021081616412079600_CIT0014","first-page":"73","article-title":"Reducing infectious complications following transrectal ultrasound-guided prostate biopsy: a systematic review","volume":"18","author":"Walker","year":"2016","journal-title":"Rev Urol"},{"key":"2021081616412079600_CIT0015","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1017\/ice.2016.174","article-title":"Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011-2014","volume":"37","author":"Weiner","year":"2016","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2021081616412079600_CIT0016","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S1286-4579(03)00049-2","article-title":"Medical and economic impact of extraintestinal infections due to Escherichia coli: focus on an increasingly important endemic problem","volume":"5","author":"Russo","year":"2003","journal-title":"Microbes Infect"},{"key":"2021081616412079600_CIT0017","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1093\/jac\/dks082","article-title":"Increasing incidence of Escherichia coli bacteraemia is driven by an increase in antibiotic-resistant isolates: electronic database study in Oxfordshire 1999-2011","volume":"67","author":"Schlackow","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"2021081616412079600_CIT0018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/668770","article-title":"Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010","volume":"34","author":"Sievert","year":"2013","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2021081616412079600_CIT0019","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1186\/1471-2334-14-393","article-title":"Antimicrobial co-resistance patterns of gram-negative bacilli isolated from bloodstream infections: a longitudinal epidemiological study from 2002-2011","volume":"14","author":"Wong","year":"2014","journal-title":"BMC Infect Dis"},{"key":"2021081616412079600_CIT0020","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12879-017-2383-z","article-title":"Carbapenem resistance, inappropriate empiric treatment and outcomes among patients hospitalized with Enterobacteriaceae urinary tract infection, pneumonia and sepsis","volume":"17","author":"Zilberberg","year":"2017","journal-title":"BMC Infect Dis"},{"key":"2021081616412079600_CIT0021","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1007\/s15010-014-0670-9","article-title":"Bloodstream infection due to extended-spectrum beta-lactamase (ESBL)-positive K. pneumoniae and E. coli: an analysis of the disease burden in a large cohort","volume":"42","author":"Leistner","year":"2014","journal-title":"Infection"},{"key":"2021081616412079600_CIT0022","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.cmi.2017.03.026","article-title":"Risk factors for extended-spectrum beta-lactamase-producing Escherichia coli urinary tract infection in the community in Denmark: a case-control study","volume":"23","author":"Sogaard","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"2021081616412079600_CIT0023","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1093\/jac\/dkw402","article-title":"Association between inappropriate empirical antimicrobial therapy and hospital length of stay in gram-negative bloodstream infections: stratification by prognosis","volume":"72","author":"Battle","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2021081616412079600_CIT0024","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.cmi.2015.05.013","article-title":"Impact of fluoroquinolone resistance in gram-negative bloodstream infections on healthcare utilization","volume":"21","author":"Brigmon","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"2021081616412079600_CIT0025","author":"Premier Applied Sciences","year":"2018"},{"key":"2021081616412079600_CIT0026","author":"3M Health Information Systems","year":"2003"},{"key":"2021081616412079600_CIT0027","article-title":"Updated coding algorithm for assessing Charlson Comorbidity Index using large hospital administrative data","author":"Rosenthal"},{"key":"2021081616412079600_CIT0028","doi-asserted-by":"crossref","first-page":"791","DOI":"10.7326\/0003-4819-137-10-200211190-00007","article-title":"Health care\u2013associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections","volume":"137","author":"Friedman","year":"2002","journal-title":"Ann Intern Med"},{"key":"2021081616412079600_CIT0029","doi-asserted-by":"crossref","first-page":"209","DOI":"10.5694\/j.1326-5377.2008.tb01586.x","article-title":"Escherichia coli bacteraemia in Canberra: incidence and clinical features","volume":"188","author":"Kennedy","year":"2008","journal-title":"Med J Aust"},{"key":"2021081616412079600_CIT0030","doi-asserted-by":"crossref","first-page":"251.e1","DOI":"10.1016\/j.cmi.2015.01.001","article-title":"Thirty day all-cause mortality in patients with Escherichia coli bacteraemia in England","volume":"21","author":"Abernethy","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"2021081616412079600_CIT0031","doi-asserted-by":"crossref","first-page":"E170","DOI":"10.1111\/j.1469-0691.2012.03845.x","article-title":"Population-based burden of bloodstream infections in Finland","volume":"18","author":"Skogberg","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"2021081616412079600_CIT0032","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/archinte.167.8.834","article-title":"Age- and sex-associated trends in bloodstream infection: a population-based study in Olmsted County, Minnesota","volume":"167","author":"Uslan","year":"2007","journal-title":"Arch Intern Med"},{"key":"2021081616412079600_CIT0033","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1186\/1471-2334-13-385","article-title":"Population-based incidence and comparative demographics of community-associated and healthcare-associated Escherichia coli bloodstream infection in Auckland, New Zealand, 2005-2011","volume":"13","author":"Williamson","year":"2013","journal-title":"BMC Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciab005\/36294841\/ciab005.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/73\/4\/565\/39763871\/ciab005.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/73\/4\/565\/39763871\/ciab005.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T16:55:27Z","timestamp":1629132927000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/73\/4\/565\/6074155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,9]]},"references-count":33,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,1,9]]},"published-print":{"date-parts":[[2021,8,16]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciab005","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,8,15]]},"published":{"date-parts":[[2021,1,9]]}}}